Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6

1.

Empowering phase II clinical trials to reduce phase III failures.

De Martini D.

Pharm Stat. 2019 Nov 14. doi: 10.1002/pst.1980. [Epub ahead of print]

PMID:
31729173
2.

Computing individual and collective ethical utility for optimally planning phase III trials.

De Capitani L, De Martini D.

Biom J. 2018 Nov;60(6):1121-1134. doi: 10.1002/bimj.201800042. Epub 2018 Sep 12.

PMID:
30209817
3.

Profit Evaluations When Adaptation by Design Is Applied.

De Martini D.

Ther Innov Regul Sci. 2016 Mar;50(2):213-220. doi: 10.1177/2168479015601720.

PMID:
30227006
4.

Stability criteria for the outcomes of statistical tests to assess drug effectiveness with a single‚ÄČstudy.

De Martini D.

Pharm Stat. 2012 Jul-Aug;11(4):273-9. doi: 10.1002/pst.1505. Epub 2012 Mar 16.

PMID:
22422716
5.

Conservative sample size estimation in nonparametrics.

De Martini D.

J Biopharm Stat. 2011 Jan;21(1):24-41. doi: 10.1080/10543400903453343.

PMID:
21191852
6.

Adapting by calibration the sample size of a phase III trial on the basis of phase II data.

Martini DD.

Pharm Stat. 2011 Mar-Apr;10(2):89-95. doi: 10.1002/pst.410.

PMID:
20140977

Supplemental Content

Loading ...
Support Center